Lyon Joseph Douglas's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Feb 5, 2025
- Accession no.
- 0000950170-25-014454
- Filed
- Feb 5, 2025
- Trade date
- Feb 3, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $334.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyon Joseph DouglasCIK 0001817838 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | Common Stock | MOption exerciseAcquired | +1,571 | $11.35 | +$17,830.85 | 10,330 | Direct | |
| Feb 3, 2025 | Common Stock | MOption exerciseAcquired | +3,429 | $13.56 | +$46,497.24 | 13,759 | Direct | |
| Feb 3, 2025 | Common Stock | SSaleDisposed | −5,000 | $66.92 | −$334,600 | 8,759 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | Common Stock | MOption exerciseDisposed | −1,571 | $0.00 | $0 | 2,596 | Direct | |
| Feb 3, 2025 | Common Stock | MOption exerciseDisposed | −3,429 | $0.00 | $0 | 96,571 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Chief Accounting & Technology Officer